Literature DB >> 12735109

Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse.

Andrew G Smith1, Reginald Davies, Timothy P Dalton, Marian L Miller, David Judah, Joan Riley, Timothy Gant, Daniel W Nebert.   

Abstract

Several forms of cytochrome P450 (CYP) appear to metabolize principally pharmaceutical agents, as well as other dietary and plant chemicals. Other CYP forms have major roles in steroid, sterol, and bile acid metabolism. CYP1A2 expression is constitutively high in mouse liver and is well known for metabolizing several drugs and many procarcinogens to reactive intermediates that can cause toxicity or cancer. CYP1A2 is also known to carry out several endogenous functions such as uroporphyrinogen and melatonin oxidation and the 2- and 4-hydroxylations of estradiol. We have used cDNA microarray analysis of the untreated Cyp1a2(-/-) knockout mouse to search for changes in gene expression that might indicate important intrinsic roles for this enzyme. For 15 of the up- or downregulated genes, these increases or decreases were corroborated by reverse-transcription real-time polymerase chain reaction. Other than upregulation of the Hprt gene (used in the selection procedure for disrupting the Cyp1a2 gene), we found several genes upregulated that are associated with cell-cycle regulation and lipid metabolism. Besides Cyp1a2, the gene exhibiting the greatest downregulation was Igfbp1 (insulin-like growth factor binding protein-1), showing only 12% expression of that in the Cyp1a2(+/+) wild-type liver. Recurrent themes between both up- and downregulated genes include cell-cycle control, insulin action, lipogenesis, and fatty acid and cholesterol biosynthetic pathways. Histologically, the Cyp1a2(-/-) mouse exhibited an approximately 50% decrease in lipid stored in hepatocytes, and 50% increase in lipid present in interstitial fat-storing cells compared with that in the Cyp1a2(+/+) wild-type. These data suggest that the CYP1A2 enzyme might perform additional hepatic endogenous functions heretofore not appreciated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12735109

Source DB:  PubMed          Journal:  EHP Toxicogenomics        ISSN: 1542-4359


  11 in total

1.  Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction.

Authors:  M C Cornelis; A El-Sohemy; H Campos
Journal:  J Med Genet       Date:  2004-10       Impact factor: 6.318

2.  Contributions of the three CYP1 monooxygenases to pro-inflammatory and inflammation-resolution lipid mediator pathways.

Authors:  Senad Divanovic; Jesmond Dalli; Lucia F Jorge-Nebert; Christopher L Karp; Charles N Serhan; Daniel W Nebert; Leah M Flick; Marina Gálvez-Peralta; Nicholas D Boespflug; Traci E Stankiewicz; Jonathan M Fitzgerald; Maheshika Somarathna
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

3.  Relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (POR) null mice.

Authors:  Xiu Jun Wang; Mark Chamberlain; Olga Vassieva; Colin J Henderson; C Roland Wolf
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

4.  Hepatic gene expression in protoporphyic Fech mice is associated with cholestatic injury but not a marked depletion of the heme regulatory pool.

Authors:  Reginald Davies; Arenda Schuurman; Colin R Barker; Bruce Clothier; Tatyana Chernova; Fiona M Higginson; David J Judah; David Dinsdale; Richard E Edwards; Peter Greaves; Timothy W Gant; Andrew G Smith
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

5.  Aryl hydrocarbon receptor-dependence of dioxin's effects on constitutive mouse hepatic cytochromes P450 and growth hormone signaling components.

Authors:  Chunja Lee; David S Riddick
Journal:  Can J Physiol Pharmacol       Date:  2012-09-14       Impact factor: 2.273

6.  Comparing gene expression during cadmium uptake and distribution: untreated versus oral Cd-treated wild-type and ZIP14 knockout mice.

Authors:  Lucia F Jorge-Nebert; Marina Gálvez-Peralta; Julio Landero Figueroa; Maheshika Somarathna; Shintaro Hojyo; Toshiyuki Fukada; Daniel W Nebert
Journal:  Toxicol Sci       Date:  2014-10-07       Impact factor: 4.849

7.  Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients.

Authors:  Giovanni Tarantino; Paolo Conca; Domenico Capone; Antonio Gentile; Giuliano Polichetti; Vincenzo Basile
Journal:  Eur J Clin Pharmacol       Date:  2006-07-14       Impact factor: 2.953

Review 8.  Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.

Authors:  Shu-Feng Zhou; Li-Ping Yang; Zhi-Wei Zhou; Ya-He Liu; Eli Chan
Journal:  AAPS J       Date:  2009-07-10       Impact factor: 4.009

9.  Hyper- and hypo-induction of cytochrome P450 activities with Aroclor 1254 and 3-methylcholanthrene in Cyp1a2(-/-) mice.

Authors:  Melissa L Barker; Laura B Hathaway; Dorinda D Arch; Mark L Westbroek; James P Kushner; John D Phillips; Michael R Franklin
Journal:  Chem Biol Interact       Date:  2009-09-20       Impact factor: 5.192

10.  Knock-in mouse lines expressing either mitochondrial or microsomal CYP1A1: differing responses to dietary benzo[a]pyrene as proof of principle.

Authors:  Hongbin Dong; Timothy P Dalton; Marian L Miller; Ying Chen; Shigeyuki Uno; Zhanquan Shi; Howard G Shertzer; Seema Bansal; Narayan G Avadhani; Daniel W Nebert
Journal:  Mol Pharmacol       Date:  2008-12-01       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.